Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)

被引：1
|
作者：
Mustacchi, G.
Bines, J.
Alba, E.
Cortes, P.
Doval, D.
de Ducla, S.
Button, P.
Gligorov, J.
机构：
[1] Univ Trieste, Trieste, Italy
[2] Inst Nacl Canc, Rio De Janeiro, Brazil
[3] Hosp Univ Clin Virgen Victoria, Malaga, Spain
[4] Univ Hosp Santa Maria, Lisbon, Portugal
[5] Rajiv Gandhi Canc Inst & Res Ctr, Delhi, India
[6] F Hoffmann Roche Ltd, Basel, Switzerland
[7] Roche Prod Ltd, Dee Why, Australia
[8] IC UPMC, APHP Tenon, Paris, France
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P5-15-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-15-06
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Overall survival (OS) results from the phase III PHENIX trial of HER2+metastatic breast cancer treated with pyrotinib plus capecitabine
    Jiang, Zefei
    Yan, Min
    Bian, Li
    Wang, Tao
    Hu, Xichun
    Zhang, Qingyuan
    Ouyang, Quchang
    Feng, Jifeng
    Yin, Yongmei
    Sun, Tao
    Tong, Zhongsheng
    Wang, Xiaojia
    Yao, Herui
    Jiang, Shuping
    Zhu, Xiaoyu
    Zou, Jianjun
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Brodowicz, T.
    Pienkowski, T.
    Beslija, S.
    Melichar, B.
    Lang, I.
    Inbar, M. J.
    Anghel, R.
    Spanik, S.
    Ahlers, S.
    Zielinski, C.
    CANCER RESEARCH, 2013, 73
  • [23] Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
    Quintela-Fandino, M.
    Manso Sanchez, L. M.
    Holgado Martin, E.
    Moreno, M. C.
    Morales Murillo, S.
    De Las Heras, B. Bermejo
    Malon Gimenez, D.
    Colomer Bosch, R.
    Gonzalez Cortijo, L.
    Hornedo, J.
    Mouron, S.
    Munoz, M.
    Escudero, S.
    Blanco, R.
    Manes, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 24 - 24
  • [24] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez Martin, A.
    de Ducla, S.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
  • [25] Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)
    Robert, Nicholas J.
    Dieras, Veronique
    Jackisch, Christian
    Srock, Stefanie
    Freudensprung, Ulrich
    Faoro, Leonardo
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2014, 74 (19)
  • [26] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    Barrios, Carlos H.
    Liu, Mei-Ching
    Lee, Soo Chin
    Vanlemmens, Laurence
    Ferrero, Jean-Marc
    Tabei, Toshio
    Pivot, Xavier
    Iwata, Hiroji
    Aogi, Kenjiro
    Lugo-Quintana, Roberto
    Harbeck, Nadia
    Brickman, Marla J.
    Zhang, Ke
    Kern, Kenneth A.
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) : 121 - 131
  • [27] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    Carlos H. Barrios
    Mei-Ching Liu
    Soo Chin Lee
    Laurence Vanlemmens
    Jean-Marc Ferrero
    Toshio Tabei
    Xavier Pivot
    Hiroji Iwata
    Kenjiro Aogi
    Roberto Lugo-Quintana
    Nadia Harbeck
    Marla J. Brickman
    Ke Zhang
    Kenneth A. Kern
    Miguel Martin
    Breast Cancer Research and Treatment, 2010, 121 : 121 - 131
  • [28] Lapatinib and paclitaxel in HER2-negative, extracellular domain (ECD) positive metastatic breast cancer (MBC) in a randomized phase III study
    Finn, R. S.
    Gagnon, R.
    Di Leo, A.
    Press, M. F.
    Arbushites, M.
    Koehler, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
    Masuda, N.
    Aogi, K.
    Ohno, S.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Ito, Y.
    Ueno, T.
    Saijo, N.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Weekly paclitaxel and capecitabine in HER2-negative metastatic breast cancer (MBC): A multicenter GINECO randomized phase II comparing two paclitaxel-capecitabine schedules
    Lortholary, A.
    Hardy-Bessard, A. C.
    Bachelot, T.
    Dalivoust, P.
    de Rauglaudre, G.
    Alexandre, J.
    Bourgeois, H.
    Jaubert, D.
    Paraiso, D.
    Largillier, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345